Provided by Tiger Trade Technology Pte. Ltd.

VanEck Biotech ETF

237.45
-1.2830-0.54%
Post-market: 237.580.1269+0.05%19:30 EDT
Volume:11.62K
Turnover:2.76M
Market Cap:474.08M
PE:- -
High:238.35
Open:238.12
Low:236.49
Close:238.74
52wk High:246.55
52wk Low:171.63
Shares:2.00M
Float Shares:2.00M
Volume Ratio:0.98
T/O Rate:0.58%
Dividend:0.95
Dividend Rate:0.40%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.21% on Oct 1: What Investors Need To Know

TradingKey
·
Oct 02

NASDAQ Top and Bottom Performing Stocks at About 02:45 P.m. EDT on 2026-10-01

Reuters
·
Oct 02

Regeneron price target raised to $930 from $870 at Jefferies

TIPRANKS
·
Oct 02

Amgen’s Pediatric Psoriasis Study in Japan Wraps Up, Setting the Stage for Otezla Growth

TIPRANKS
·
Oct 02

Expanded Sanofi agreement particularly favorable for Regeneron, says TD Cowen

TIPRANKS
·
Oct 02

Walt Disney, Amgen Share Losses Lead Dow's 150-Point Fall

Dow Jones
·
Oct 02

Regeneron says COURAGE trial confirms trevogrumab prevents muscle loss

TIPRANKS
·
Oct 01

Regeneron Pharmaceuticals, - 9-Month Median Duration of Response Observed at 800 Mg Ubamatamab Dose

THOMSON REUTERS
·
Oct 01

Regeneron Pharmaceuticals, - Ubamatamab Shows 73% Objective Response Rate and 11-Month Median Pfs in Lgsoc Patients

THOMSON REUTERS
·
Oct 01

Regeneron Pharmaceuticals, - Serious Teaes Grade 3+ in 21% of Lgsoc Patients; Traes in 74%; Neutropenia, Anemia, Elevated Liver Enzymes

THOMSON REUTERS
·
Oct 01

Regeneron Pharmaceuticals, - to Advance Ubamatamab into Confirmatory Phase 3 Trial for Lgsoc

THOMSON REUTERS
·
Oct 01

Ubamatamab (Muc16xcd3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (Lgsoc)

THOMSON REUTERS
·
Oct 01

Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)

GlobeNewswire
·
Oct 01

Regeneron Says Phase 2 Courage Trial Shows Trevogrumab Preserves Lean Mass During Semaglutide Weight Loss

Reuters
·
Oct 01

Regeneron Pharmaceuticals, - Lower Doses of Trevogrumab Well Tolerated with 77% Experiencing at Least One Adverse Event

THOMSON REUTERS
·
Oct 01

Regeneron Pharmaceuticals, - Plans Phase 2 Trial of Trevogrumab with Glp-1 Therapies in Older Adults

THOMSON REUTERS
·
Oct 01

Phase 2 Courage Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During Glp-1 Receptor Agonist-Induced Weight Loss

THOMSON REUTERS
·
Oct 01

Regeneron Pharmaceuticals, - Trevogrumab Prevents 70% of Muscle Loss Associated with Semaglutide Treatment

THOMSON REUTERS
·
Oct 01

Gilead Sciences Announces Dividend of R$ 0.2394442440 Per Unit for Brgildbdr 000

Reuters
·
Oct 01

Regeneron Exec Says Co Eligible to Receive $1 Bln in Potential Milestone Payment with the Start of the First Late-Stage Trial as Part of the Deal -Conf Call

THOMSON REUTERS
·
Oct 01